MX2012000466A - Metodo y composiciones farmaceuticas para el tratamiento de la hiperglicemia postprandial de la diabetes tipo ii, a traves de la mucosa bucal. - Google Patents

Metodo y composiciones farmaceuticas para el tratamiento de la hiperglicemia postprandial de la diabetes tipo ii, a traves de la mucosa bucal.

Info

Publication number
MX2012000466A
MX2012000466A MX2012000466A MX2012000466A MX2012000466A MX 2012000466 A MX2012000466 A MX 2012000466A MX 2012000466 A MX2012000466 A MX 2012000466A MX 2012000466 A MX2012000466 A MX 2012000466A MX 2012000466 A MX2012000466 A MX 2012000466A
Authority
MX
Mexico
Prior art keywords
diabetes
type
trans
buccal mucosa
pharmaceutical compositions
Prior art date
Application number
MX2012000466A
Other languages
English (en)
Other versions
MX337606B (es
Inventor
Philippe Perovitch
Marc Maury
Jean-Pierre Dumonteix
Original Assignee
Philippe Perovitch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philippe Perovitch filed Critical Philippe Perovitch
Publication of MX2012000466A publication Critical patent/MX2012000466A/es
Publication of MX337606B publication Critical patent/MX337606B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un método y una composición farmacéutica en forma de una solución hidroalcohólica en la cual se disuelve de forma estable y completa al menos un principio activo hipoglicemiante/insulinotropo a una dosis reducida en 30 a 50% con relación a la dosis unitaria usual para vía oral, para su aplicación a través de la mucosa bucal en el tratamiento puntual de la HiperGlicemia Post-Prandial de la Diabetes de Tipo II en humanos o animales. La invención se relaciona igualmente con un método de preparación de esta formulación y a su uso específico para el tratamiento puntual de la HiperGlicemia PostPrandial (HGPP) en el contexto de la Diabetes de Tipo II.
MX2012000466A 2009-07-10 2010-07-07 Metodo y composiciones farmaceuticas para el tratamiento de la hiperglicemia postprandial de la diabetes tipo ii, a traves de la mucosa bucal. MX337606B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0954819A FR2947729B1 (fr) 2009-07-10 2009-07-10 Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale
PCT/FR2010/051426 WO2011004117A1 (fr) 2009-07-10 2010-07-07 Procédé et compositions pharmaceutiques pour le traitement de l'hyper glycémie post-prandiale du diabète de type ii par voie trans-muqueuse buccale

Publications (2)

Publication Number Publication Date
MX2012000466A true MX2012000466A (es) 2012-04-19
MX337606B MX337606B (es) 2016-03-10

Family

ID=41571558

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000466A MX337606B (es) 2009-07-10 2010-07-07 Metodo y composiciones farmaceuticas para el tratamiento de la hiperglicemia postprandial de la diabetes tipo ii, a traves de la mucosa bucal.

Country Status (10)

Country Link
US (1) US9161910B2 (es)
EP (1) EP2451436A1 (es)
JP (1) JP2012532852A (es)
CN (1) CN102481254A (es)
BR (1) BR112012000596A2 (es)
FR (1) FR2947729B1 (es)
IN (1) IN2012DN00977A (es)
MX (1) MX337606B (es)
RU (1) RU2543635C2 (es)
WO (1) WO2011004117A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2940116B1 (fr) * 2008-12-22 2012-07-06 Philippe Perovitch Formulation pour l'administration d'hypolipemiant par voie trans-muqueuse buccale
FR3000896B1 (fr) * 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
FR3031668A1 (fr) 2015-01-20 2016-07-22 Philippe Perovitch Dispositif d'administration d'un principe actif par voie per-muqueuse buccale.
FR3053244A1 (fr) 2016-07-01 2018-01-05 Philippe Perovitch Dispositif d'administration d'au moins un principe actif par voie per-muqueuse buccale.
CN107669683B (zh) * 2017-09-30 2020-07-03 杭州华东医药集团新药研究院有限公司 含有西格列汀与二甲双胍的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2071779C1 (ru) * 1993-05-12 1997-01-20 Хабаровский химико-фармацевтический завод Способ получения пантокрина для инъекций
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US7411089B2 (en) * 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
SE528866C2 (sv) * 2005-07-01 2007-02-27 Volvo Lastvagnar Ab Anordning för att kontrollera höjden hos en last eller lastbärare bakom förarhytten hos en lastbil
CN101263107A (zh) * 2005-08-30 2008-09-10 艾博特公司 作为二肽基肽酶-iv(dpp-iv)抑制剂的药物组合物
DE102006027790A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Typ-2-Diabetes Kombinations-Wafer
CA2659245A1 (en) * 2006-07-28 2008-01-31 Novadel Pharma Inc. Anti-migraine oral spray formulations and methods
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs

Also Published As

Publication number Publication date
US9161910B2 (en) 2015-10-20
FR2947729A1 (fr) 2011-01-14
IN2012DN00977A (es) 2015-04-10
EP2451436A1 (fr) 2012-05-16
US20120190618A1 (en) 2012-07-26
MX337606B (es) 2016-03-10
WO2011004117A1 (fr) 2011-01-13
BR112012000596A2 (pt) 2016-02-10
FR2947729B1 (fr) 2012-01-20
RU2012104639A (ru) 2013-08-20
CN102481254A (zh) 2012-05-30
RU2543635C2 (ru) 2015-03-10
JP2012532852A (ja) 2012-12-20

Similar Documents

Publication Publication Date Title
BR112014012815A2 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
IL195030A (en) IV dpp inhibitor assemblies
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
NO20084919L (no) Oksadiazolidindionforbindelse
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
MX2009004362A (es) Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk.
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
IN2012DN01233A (es)
WO2012125830A3 (en) Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
PH12019501251A1 (en) Novel phenyl propionic acid derivatives and uses thereof
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
MX340985B (es) Compuestos de n-heteroarilo.
MX2017004614A (es) Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas.
MY148878A (en) Stabilized amorphous forms of imatinib mesylate
WO2008084504A3 (en) Pharmaceutical compositions of angiotensin ii receptor blockers
MX337606B (es) Metodo y composiciones farmaceuticas para el tratamiento de la hiperglicemia postprandial de la diabetes tipo ii, a traves de la mucosa bucal.
WO2007012479A3 (en) Benzylpiperazine derivates and their medical use
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
GB0611907D0 (en) Compounds
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
MX2010006215A (es) Derivados de piperazina y su uso como moduladores del receptor de leptina.
MX2010006216A (es) Nuevos compuestos iii.
EA201290485A1 (ru) Производные бензамида

Legal Events

Date Code Title Description
FG Grant or registration